1.Assessment of the physical status of elderly patients with prostate cancer.
National Journal of Andrology 2017;23(12):1132-1137
Prostate cancer (PCa) is the primary malignancy threatening men's health in the United States and its incidence is increasing in China year by year. Many PCa cases are found in the advanced stage or in the old age, treated with unstandardized options, with negligence of comprehensive assessment of the patient's physical status, which may frequently add to the physical, psychological and economic burdens of the patient and even result in death. On the other hand, some excessively conservative therapeutic options may cause the loss of the best time of management or lead to deterioration of the disease. Therefore, sufficient importance should be attached to the comprehensive assessment of the physical status of the elderly PCa patient before treatment and the choice of the best therapeutic protocol.
Aged
;
China
;
epidemiology
;
Conservative Treatment
;
Humans
;
Incidence
;
Male
;
Physical Fitness
;
Prostatic Neoplasms
;
epidemiology
;
pathology
;
therapy
;
United States
;
epidemiology
2.Comparisons of the incidence and pathological characteristics of prostate cancer between Chinese and Portuguese in Macau.
Lap Hong IAN ; Hong LI ; Yong YANG ; Chun-fat HO
Chinese Medical Journal 2008;121(4):292-294
BACKGROUNDAging of population in Macau has become a serious problem and we are diagnosing more and more patients with prostate cancer. To investigate the effect of ethnicity and environment on incidence of prostate carcinoma, we compared the difference of biopsy and postoperative pathology of prostate between indigenous Chinese (Chinese) and Chinese of Portuguese descent (Portuguese) with elevated serologic prostate specific antigen (PSA) and incidence of prostate carcinoma in Macau.
METHODSBetween 1999 and 2006, prostate biopsy was performed in a random sample of 462 patients with elevated serologic PSA who, on followup, were diagnosed in this hospital with benign prostate hyperplasia. Of these, 416 were indigenous Chinese, 46 Portuguese. Based on demographic statistics by Macau government for 2005, we compared differences in incidences of prostate carcinoma, positive rate of random prostate biopsy in patients with elevated serologic PSA, factors related to serological PSA and pathological grade and stage between both ethnic groups.
RESULTSProstate carcinoma was diagnosed on biopsy in 178 cases. Positive biopsies of prostate carcinoma were present in 160 Chinese with positive rate of 38.5% and in 18 Portuguese with 39.1%. For patients diagnosed with prostate carcinoma, there was no significant difference in age, incidence, grade of cancerous cells, stage of the disease, incidence of inflammation of prostatic tissues or prostatic intraepithelial neoplasia (PIN) related to elevated PSA between the groups (All P>0.05).
CONCLUSIONSThere was no significant difference in incidence or characteristics of prostate carcinoma between people of Portuguese and Chinese descent in Macau based on our limited data. Long term residence in the same environment may be associated with the incidence and progression of prostate carcinoma in Portuguese living in Macau, but further rigorous epidemiological investigation and analysis of risk factors about prostate carcinoma are needed to corroborate this conclusion.
Aged ; China ; ethnology ; Humans ; Incidence ; Macau ; epidemiology ; Male ; Middle Aged ; Portugal ; ethnology ; Prostatic Neoplasms ; blood ; epidemiology ; pathology
3.The influence of benign prostatic hyperplasia drugs on incidence and pathology grading of prostate cancer.
Jie ZHU ; Jiang-ping GAO ; A-xiang XU ; Xian-yu LÜ ; Liang CUI ; Bao-fa HONG ; Xu ZHANG
Chinese Journal of Surgery 2010;48(10):761-763
OBJECTIVETo analyze the influence of benign prostatic hyperplasia (BPH) drugs on incidence and pathology grading of prostate cancer in China.
METHODSRetrospectively investigated the history of drug treatment in 1029 cases of BPH in patients from February 1998 to December 2004. According to the history of drug use, the patients were divided into 4 groups: finasteride group, alpha-receptor inhibitor group, finasteride and alpha-receptor inhibitor combination group and control group (untreated group). We gathered pathology sections of patients in all groups, and gave Gleason Score to each. The difference of incidence and pathology grading of prostate cancer were analyzed by Stata 7.0.
RESULTSThe incidence of prostate cancer in the population of our study was 13.5%; The incidence in finasteride group, alpha-receptor inhibitor group, combination group and control group was 9.8%, 16.0%, 10.3% and 18.6%, respectively. There was significant difference between the two groups with the use of finasteride and the two groups without it (P < 0.05). In our study, the ratio of middle or high level pathology grading (Gleason ≥ 7) in prostate cancer patients was 58.3%, the ratio of middle or high level pathology grading prostate cancer patients in the four groups was 71.4%, 59.6%, 67.7% and 40.0%, respectively. In the comparison of composition ratio of middle or high level prostate cancer, there was significant difference between the two groups with the use of finasteride and the two groups without it (P < 0.05).
CONCLUSIONSFinasteride can lower the risk of prostate cancer, but increase the pathology grade of the prostate cancer which has occurred in the same time. The alpha-receptor inhibitor does not have the same effect.
Adrenergic alpha-Antagonists ; therapeutic use ; Aged ; Aged, 80 and over ; Finasteride ; therapeutic use ; Humans ; Incidence ; Male ; Middle Aged ; Prostatic Hyperplasia ; drug therapy ; Prostatic Neoplasms ; epidemiology ; pathology ; Retrospective Studies
4.Incidental prostate cancer in radical cystoprostatectomy specimens.
Xiao-Dong JIN ; Zhao-Dian CHEN ; Bo WANG ; Song-Liang CAI ; Xiao-Lin YAO ; Bai-Ye JIN
Asian Journal of Andrology 2008;10(5):809-814
AIMTo investigate the rates of prostate cancer (PCa) in radical cystoprostatectomy (RCP) specimens for bladder cancer in mainland China. To determine the follow-up outcome of patients with two concurrent cancers and identify whether prostate-specific antigen (PSA) is a useful tool for the detection of PCa prior to surgery.
METHODSFrom January 2002 to January 2007, 264 male patients with bladder cancer underwent RCP at our center. All patients underwent digital rectal examination (DRE) and B ultrasound. Serum PSA levels were tested in 168 patients. None of the patients had any evidence of PCa before RCP. Entire prostates were embedded and sectioned at 5 mm intervals.
RESULTSIncidental PCa was observed in 37 of 264 (14.0%) RCP specimens. Of these, 12 (32.4%) were clinically significant according to an accepted definition. The PSA levels were not significantly different between patients with PCa and those without PCa, nor between patients with significant PCa and those with insignificant PCa. Thirty-four patients with incidental PCa were followed up. During a mean follow-up period of 26 months, two patients with PSA > 4 ng/mL underwent castration. None of the patients died of PCa.
CONCLUSIONThe incidence of PCa in RCP specimens in mainland China is lower than that in most developed countries. PSA cannot identify asymptomatic PCa prior to RCP. In line with published reports, incidental PCa does not impact the prognosis of bladder cancer patients undergoing RCP.
Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor ; blood ; China ; epidemiology ; Cystectomy ; Humans ; Incidence ; Incidental Findings ; Male ; Middle Aged ; Neoplasms, Second Primary ; epidemiology ; pathology ; surgery ; Prognosis ; Prostate-Specific Antigen ; blood ; Prostatectomy ; Prostatic Neoplasms ; blood ; epidemiology ; pathology ; Urinary Bladder Neoplasms ; epidemiology ; pathology ; surgery
5.Interval from Prostate Biopsy to Radical Prostatectomy Does Not Affect Immediate Operative Outcomes for Open or Minimally Invasive Approach.
Bumsoo PARK ; Seol Ho CHOO ; Hwang Gyun JEON ; Byong Chang JEONG ; Seong Il SEO ; Seong Soo JEON ; Hyun Moo LEE ; Han Yong CHOI
Journal of Korean Medical Science 2014;29(12):1688-1693
Traditionally, urologists recommend an interval of at least 4 weeks after prostate biopsy before radical prostatectomy. The aim of our study was to evaluate whether the interval from prostate biopsy to radical prostatectomy affects immediate operative outcomes, with a focus on differences in surgical approach. The study population of 1,848 radical prostatectomy patients was divided into two groups according to the surgical approach: open or minimally invasive. Open group included perineal and retropubic approach, and minimally invasive group included laparoscopic and robotic approach. The cut-off of the biopsy-to-surgery interval was 4 weeks. Positive surgical margin status, operative time and estimated blood loss were evaluated as endpoint parameters. In the open group, there were significant differences in operative time and estimated blood loss between the <4-week and > or =4-week interval subgroups, but there was no difference in positive margin rate. In the minimally invasive group, there were no differences in the three outcome parameters between the two subgroups. Multivariate analysis revealed that the biopsy-to-surgery interval was not a significant factor affecting immediate operative outcomes in both open and minimally invasive groups, with the exception of the interval > or =4 weeks as a significant factor decreasing operative time in the minimally invasive group. In conclusion, performing open or minimally invasive radical prostatectomy within 4 weeks of prostate biopsy is feasible for both approaches, and is even beneficial for minimally invasive radical prostatectomy to reduce operative time.
Humans
;
Male
;
Middle Aged
;
Minimally Invasive Surgical Procedures/*statistics & numerical data
;
*Operative Time
;
Postoperative Hemorrhage/*epidemiology
;
Prevalence
;
Prostatectomy/*statistics & numerical data
;
Prostatic Neoplasms/epidemiology/*pathology/*surgery
;
Republic of Korea/epidemiology
;
Retrospective Studies
;
Time-to-Treatment/*statistics & numerical data
;
Treatment Outcome
6.Clinicopathologic Differences Between Prostate Cancers Detected During Initial and Repeat Transrectal Ultrasound-Guided Biopsy in Korea.
Dong Jin PARK ; Ki Ho KIM ; Tae Gwon KWON ; Chun Il KIM ; Cheol Hee PARK ; Jae Shin PARK ; Duck Youn KIM ; Jae Soo KIM ; Ki Hak MOON ; Kyung Seop LEE
Korean Journal of Urology 2014;55(11):718-724
PURPOSE: The aim of this study was to investigate clinicopathologic differences between prostate cancer (PCa) detected at initial and repeat transrectal ultrasound-guided prostate biopsy in a large Korean cohort. MATERIALS AND METHODS: From 2000 through 2012, a total of 7,001 patients underwent transrectal ultrasound-guided prostate biopsy at 6 centers in Daegu and Gyeongbuk provinces. Of these 7,001 patients, the initial biopsy was positive for PCa in 2,118 patients. Repeat biopsy was performed in 374 of the 4,883 patients with an initial negative finding and a persistently elevated prostate-specific antigen (PSA) level, nodules or asymmetry by digital rectal examination (DRE), high-grade prostatic intraepithelial neoplasia, or atypical small acinar proliferation. Numbers of biopsy cores varied from 6 to 12 according to center and biopsy date. RESULTS: Cancer was diagnosed in 2,118 of the 7,001 patients (30.3%) at initial biopsy and in 86 of the 374 patients (23.0%) at repeat biopsy. The repeat biopsy rate was 5.3%. Mean PSA values were 68.7+/-289.5 ng/mL at initial biopsy and 18.0+/-55.4 ng/mL at repeat biopsy (p<0.001). The mean number of cancer-positive cores per biopsy was 5.5+/-3.5 for initial biopsy and 3.0+/-2.9 for repeat biopsy (p<0.001). Mean Gleason score was 7.5+/-1.4 at initial biopsy and 6.6+/-1.3 at repeat biopsy (p<0.001). For detected cancers, the low-stage rate was higher for repeat biopsy than for initial biopsy (p=0.001). CONCLUSIONS: Cancers detected at repeat biopsy tend to have lower Gleason scores and stages than cancers detected at initial biopsy. The present study shows that repeat biopsy is needed in patients with a persistently high PSA or abnormal DRE findings.
Adult
;
Aged
;
Aged, 80 and over
;
Endosonography/*methods
;
Follow-Up Studies
;
Humans
;
Image-Guided Biopsy/*methods
;
Incidence
;
Male
;
Middle Aged
;
Neoplasm Grading
;
Neoplasm Staging
;
Prostatic Neoplasms/epidemiology/*pathology
;
Rectum
;
Reproducibility of Results
;
Republic of Korea/epidemiology
;
Retrospective Studies
7.Suitable reference genes for relative quantification of miRNA expression in prostate cancer.
Annika SCHAEFER ; Monika JUNG ; Kurt MILLER ; Michael LEIN ; Glen KRISTIANSEN ; Andreas ERBERSDOBLER ; Klaus JUNG
Experimental & Molecular Medicine 2010;42(11):749-758
Real time quantitative PCR (qPCR) is the method of choice for miRNA expression studies. For relative quantification of miRNAs, normalization to proper reference genes is mandatory. Currently, no validated reference genes for miRNA qPCR in prostate cancer are available. In this study, the expression of four putative reference genes (hsa-miR-16, hsa-miR-130b, RNU6-2, SNORD7) was examined with regard to their use as normalizer. After SNORD7 was already shown an inappropriate reference gene in preliminary experiments using total RNA pools, we studied the expression of the putative reference genes in tissue and normal adjacent tissue sample pairs from 76 men with untreated prostate carcinoma collected after radical prostatectomy. hsa-miR-130b and RNU6-2 showed no significantly different expression between the matched malignant and non-malignant tissue samples, whereas hsa-miR-16 was significantly underexpressed in malignant tissue. Softwares geNorm and Normfinder predicted hsa-miR-130b and the geometric mean of hsa-miR-130b and RNU6-2 as the most stable reference genes. Normalization of the four miRNAs hsa-miR-96, hsa-miR-125b, hsa-miR-205, and hsa-miR-375, which were previously shown to be regulated, shows that normalization to hsa-mir-16 can lead to biased results. We recommend using hsa-miR-130b or the geometric mean of hsa-miR-130b and small RNA RNU6-2 for normalization in miRNA expression studies of prostate cancer.
Aged
;
Bias (Epidemiology)
;
Carcinoma/diagnosis/*genetics/pathology
;
Diagnostic Errors/prevention & control
;
Gene Expression Profiling
;
Gene Expression Regulation, Neoplastic
;
Humans
;
Male
;
MicroRNAs/genetics/*metabolism
;
Middle Aged
;
Polymerase Chain Reaction
;
Prostatic Neoplasms/diagnosis/*genetics/pathology
;
*Reference Standards
8.Prevalence and clinical significance of incidental 18F-fluoro-2-deoxyglucose uptake in prostate.
Taekmin KWON ; In Gab JEONG ; Dalsan YOU ; Jun Hyuk HONG ; Hanjong AHN ; Choung Soo KIM
Korean Journal of Urology 2015;56(4):288-294
PURPOSE: To investigate the prevalence and clinical significance of incidental prostate fluoro-2-deoxyglucose (FDG) uptake and to evaluate its impact on patient management. MATERIALS AND METHODS: Of 47,109 men who underwent FDG positron emission tomography between 2004 and 2014, 1,335 (2.83%) demonstrated incidental FDG uptake in the prostate, with 99 of the latter undergoing prostate biopsy. The primary end point was the histological presence of prostate adenocarcinoma in the biopsy specimen. Outcomes, including treatment methods, survival, and causes of death, were also assessed. Factors associated with the diagnosis of prostate cancer were evaluated by using logistic regression analysis. RESULTS: Patients with prostate cancer were more likely to have higher serum prostate-specific antigen (PSA) (p=0.001) and focal FDG uptake (p=0.036) than were those without. Prostate cancer occurred in 1 of 26 patients (3.8%) with serum PSA<2.5 ng/mL, compared with 40 of 67 patients (59.7%) with serum PSA> or =2.5 ng/mL. Multivariable analysis showed that focal lesions (odds ratio [OR], 5.50; p=0.038), age (OR, 1.06; p=0.031), and serum PSA (OR, 1.28; p=0.001) were independent predictors of prostate cancer diagnosis. Most patients with prostate cancer had organ-confined tumors. Of these, 12 (29.3%) underwent radical prostatectomy and 25 (60.9%) received hormone therapy. Of the 11 patients who died, 9 died of primary cancer progression, with only 1 patient dying from prostate cancer. CONCLUSIONS: The prevalence of incidental FDG uptake in the prostate was not high, although patients with elevated serum PSA had a higher incidence of prostate cancer. Patients with FDG uptake in the prostate should be secondarily evaluated by measuring serum PSA, with those having high serum PSA undergoing prostate biopsy.
*Adenocarcinoma/epidemiology/pathology/surgery
;
Aged
;
Biopsy
;
Fluorodeoxyglucose F18/*pharmacokinetics
;
Humans
;
Incidental Findings
;
Male
;
Middle Aged
;
Organ Specificity
;
Positron-Emission Tomography/*adverse effects
;
Prevalence
;
*Prostate/drug effects/pathology
;
Prostatectomy/methods/statistics & numerical data
;
*Prostatic Neoplasms/epidemiology/pathology/surgery
;
Radiopharmaceuticals/pharmacokinetics
;
Republic of Korea/epidemiology
;
Retrospective Studies
;
Tissue Distribution
9.Complications of Transrectal Ultrasound-Guided Prostate Biopsy: Impact of Prebiopsy Enema.
Sung Chul KAM ; See Min CHOI ; Sol YOON ; Jae Hui CHOI ; Seong Hyun LEE ; Jeong Seok HWA ; Ky Hyun CHUNG ; Jae Seog HYUN
Korean Journal of Urology 2014;55(11):732-736
PURPOSE: Transrectal ultrasound (TRUS)-guided biopsy of the prostate is usually safe. However, some patients are hospitalized owing to complications from TRUS biopsy. We identified the risk factors for complications and effective preventive measures for treating complications after TRUS biopsy. MATERIALS AND METHODS: Medical records and radiological images of 1,083 patients who underwent TRUS biopsy of the prostate over 10 years in Gyeongsang National University Hospital were examined retrospectively to investigate the correlation between complications after TRUS biopsy and preventive antibiotics, prebiopsy enema, number of biopsy cores, and pathological findings. RESULTS: Complications occurred in 69 patients (6.4%). The complication rates of the 1,008 patients who received antibiotics and the 75 patients who did not were 6.3% and 8.0%, respectively (p=0.469). Complication rates of the pre-biopsy enema group (n=658) and the group without prebiopsy enema (n=425) were 4.7% and 8.9%, respectively (p=0.007). Complication rates of the 6-core biopsy group (n=41) and the 12-core biopsy group (n=955) were 7.3% and 6.3%, respectively (p=0.891). Complication rates of the prostate cancer group (n=306) and the no prostate cancer group (n=713) were 6.2% and 6.6%, respectively (p=0.740). CONCLUSIONS: A prebiopsy enema was associated with a reduced risk of complications after TRUS biopsy. Preventive antibiotics, number of biopsy cores, and pathological findings did not significantly influence the complication rate.
Aged
;
*Endosonography
;
Enema/*methods
;
Humans
;
Image-Guided Biopsy/*adverse effects/methods
;
Incidence
;
Male
;
Prostatic Neoplasms/*pathology
;
Prostatitis/epidemiology/etiology/*prevention & control
;
Rectum
;
Republic of Korea/epidemiology
;
Retrospective Studies
;
Risk Factors
;
Syncope, Vasovagal/epidemiology/etiology/*prevention & control
;
Urinary Retention/epidemiology/etiology/*prevention & control
10.Radical Prostatectomy in Korean Men Aged 75-Years or Older: Safety and Efficacy in Comparison with Patients Aged 65-69 Years.
Jae Hyun RYU ; Yun Beom KIM ; Tae Young JUNG ; Sun Il KIM ; Seok Soo BYUN ; Dong Deuk KWON ; Duk Yoon KIM ; Tae Hee OH ; Tag Keun YOO ; Woo Jin KO
Journal of Korean Medical Science 2016;31(6):957-962
Prostate cancer is the most common type of male cancer worldwide. Although radical prostatectomy (RP) is advised for prostate cancer in patients with a life expectancy of more than 10 years by various guidelines, most elderly men still do not undergo the procedure regardless of increasing life expectancy. This study aimed to determine whether RP is suitable for patients with prostate cancer aged 75 years or older. A retrospective study of patients who underwent RP at 6 institutions between 2005 and 2012 was conducted. Patients were divided into 2 groups at the time of surgery: 65-69 years (younger group) and 75 years or older (older group). We compared clinical characteristics, pathological results, complication rates, and recurrence-free survival between the two groups. Compared with the younger group, the older group had significantly higher preoperative serum prostate-specific antigen level, pre- and postoperative Eastern Cooperative Oncology Group (ECOG) performance status grade, hypertension prevalence, and Gleason score at biopsy and RP. However, except urinary incontinence, there were no statistically significant differences in the peri- and post-operative complications. After median follow-up periods of 36 months (younger group) and 40 months (older group), the biochemical recurrence-free survival rates were not significantly different (P = 0.581). Although the urinary incontinence rate was higher in the older group, RP was a suitable option for selected Korean men aged 75 years or older with limited complication rates and excellent outcomes similar to those for patients aged 65-69 years.
Age Factors
;
Aged
;
Biopsy
;
Disease-Free Survival
;
Humans
;
Hypertension/epidemiology
;
Male
;
Middle Aged
;
Multivariate Analysis
;
Neoplasm Grading
;
Prostate-Specific Antigen/blood
;
Prostatectomy
;
Prostatic Neoplasms/mortality/pathology/*surgery
;
Republic of Korea
;
Retrospective Studies